Miroslawa Puskulluoglu - Publications

Emerging immune checkpoint inhibitor strategies in cervical cancer: a scoping review of ongoing clinical trials.

Journal: Expert review of anticancer therapy

Published: May 19, 2026

Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study.

Journal: The oncologist

Published: May 07, 2026

The Prognostic Potential of PD-L1, PD-1, CD3, CD4, and CD8 Expression in Patients with Head and Neck Cancers Depending on HPV16 Infection.

Journal: Cancers

Published: April 14, 2026

Cyclin-dependent kinase 4/6 inhibitors in granulosa cell tumors and their combination with hormonal therapy: a scoping review.

Journal: Frontiers in oncology

Published: March 31, 2026

Immune-Related Adverse Events of Cemiplimab Therapy in Advanced Cervical Cancer-Data from the Polish-Czech Cervical Cancer Immunotherapy Group (PCCIG-01) with a Review of the Literature.

Journal: Antibodies (Basel, Switzerland)

Published: March 26, 2026

Association of PD-L1 combined positive score with disease control and response kinetics with first-line pembrolizumab-based therapy in metastatic triple-negative breast cancer: results from routine clinical practice in Poland.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 25, 2026

Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from CEBCC-102 study.

Journal: Journal of neuro-oncology

Published: December 03, 2025

Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe.

Journal: The oncologist

Published: November 23, 2025

Editorial: Bispecific antibodies and their conjugates in solid tumors and hematological malignancies.

Journal: Frontiers in immunology

Published: November 23, 2025

Impact of Germline BRCA1/2 Mutations on Clinical Outcomes in Metastatic Triple-Negative Breast Cancer Patients Treated with Sacituzumab Govitecan-An International CEBCC Study from Poland, the Czech Republic and Slovakia.

Journal: Oncology research

Published: November 19, 2025

Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 17, 2025

Timing of final oncologist visit and systemic treatment use near the end of life in pretreated patients with metastatic triple-negative breast cancer: a multinational cohort study.

Journal: Breast (Edinburgh, Scotland)

Published: October 28, 2025